Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Change of Patient-Reported Aesthetic Outcome Over Time and Identification of Factors Characterizing Poor Aesthetic Outcome After Breast-Conserving Therapy: Long-Term Results of a Prospective Cohort Study.
Hennigs A, Biehl H, Rauch G, Golatta M, Tabatabai P, Domschke C, Schott S, Wallwiener M, Schütz F, Sohn C, Heil J. Hennigs A, et al. Ann Surg Oncol. 2016 May;23(5):1744-51. doi: 10.1245/s10434-015-4943-z. Epub 2015 Nov 6. Ann Surg Oncol. 2016. PMID: 26545376
Predictors of early poor aesthetic outcome after breast-conserving surgery in patients with breast cancer: initial results of a prospective cohort study at a single institution.
Foersterling E, Golatta M, Hennigs A, Schulz S, Rauch G, Schott S, Domschke C, Schuetz F, Sohn C, Heil J. Foersterling E, et al. Among authors: hennigs a. J Surg Oncol. 2014 Dec;110(7):801-6. doi: 10.1002/jso.23733. Epub 2014 Aug 8. J Surg Oncol. 2014. PMID: 25132148 Clinical Trial.
Long-term objective esthetic outcome after breast-conserving therapy.
Hennigs A, Hartmann B, Rauch G, Golatta M, Tabatabai P, Domschke C, Schott S, Schütz F, Sohn C, Heil J. Hennigs A, et al. Breast Cancer Res Treat. 2015 Sep;153(2):345-51. doi: 10.1007/s10549-015-3540-y. Epub 2015 Aug 13. Breast Cancer Res Treat. 2015. PMID: 26267662
Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
Stefanovic S, Diel I, Sinn P, Englert S, Hennigs A, Mayer C, Schott S, Wallwiener M, Blumenstein M, Golatta M, Heil J, Rom J, Sohn C, Schneeweiss A, Schuetz F, Domschke C. Stefanovic S, et al. Among authors: hennigs a. Ann Surg Oncol. 2016 Mar;23(3):757-66. doi: 10.1245/s10434-015-4895-3. Epub 2015 Oct 14. Ann Surg Oncol. 2016. PMID: 26467455
Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.
von Au A, Milloth E, Diel I, Stefanovic S, Hennigs A, Wallwiener M, Heil J, Golatta M, Rom J, Sohn C, Schneeweiss A, Schuetz F, Domschke C. von Au A, et al. Among authors: hennigs a. Onco Targets Ther. 2016 Jul 8;9:4173-80. doi: 10.2147/OTT.S103130. eCollection 2016. Onco Targets Ther. 2016. PMID: 27468239 Free PMC article.
Do Contralateral Prophylactic Mastectomies Help Patients?
Heil J, Kneser U, Hennigs A, Bieber C, Gschwendtner K, Mueller N, Rauch G, Schuetz F, Sohn C, Kremer T. Heil J, et al. Among authors: hennigs a. J Clin Oncol. 2016 Dec;34(34):4191. doi: 10.1200/JCO.2016.68.2997. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621389 No abstract available.
84 results